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Abstract
Background: Amphiregulin (AREG) and Epiregulin (EREG), ligands of EGFR, are reported to be predictive
biomarkers of colorectal cancer patients treated with Cetuximab, an anti-EGFR antibody. The purpose of this study
is to determine the correlation of AREG and EREG expression between primary colorectal cancer and
corresponding liver metastases.
Methods: One hundred twenty colorectal cancer patients with liver metastases (100 with synchronous metastases,
20 with metachronous) were evaluated. No patients had ever received anti-EGFR antibody agents. AREG and EREG
mRNA expression from both the primary tumor and liver metastases were measured using real-time RT-PCR. KRAS
codon 12, 13 mutation status was analyzed by direct sequencing.
Results: Modest, but significant, correlations were observed between primary tumor and corresponding liver
metastases in both AREG mRNA expression (Rs = 0.54, p < 0.0001) and EREG mRNA expression (Rs = 0.58, p <
0.0001). AREG and EREG mRNA expression was strongly correlated in both the primary tumor (Rs = 0.81, p <
0.0001) and the liver metastases (Rs = 0.87, p < 0.0001). No significant survival difference was observed between
low and high AREG or EREG patients when all 120 patients were analyzed. However, when divided by KRAS status,
KRAS wild-type patients with low EREG mRNA levels in the primary site showed significantly better overall survival
rates than those with high levels (p = 0.018). In multivariate analysis, low EREG expression was significantly
associated with better overall survival (p = 0.006).
Conclusions: AREG and EREG expression showed a modest correlation between primary tumor and liver
metastases. As EREG mRNA expression was associated with decreased survival, it is appeared to be a useful
prognostic marker in KRAS wild-type patients who never received anti-EGFR therapy.
Background
Epidermal growth factor receptor (EGFR) is known to
be involved in signaling pathways affecting cellular
growth, differentiation, and proliferation [1]. To block
the activation of this receptor, the anti-EGFR antibody
agents Cetuximab and Panitumumab have been devel-
oped, and offer promising results for cases of metastatic
colorectal cancer (CRC) [2-4]. Recently, several clinical
trials demonstrated that somatic mutations in KRAS are
associated with a lack of sensitivity to anti-EGFR anti-
body agents [5-7], suggesting that KRAS is a definite
predictive biomarker for anti-EGFR antibody. However,
even in patients with KRAS wild-type tumors, the
response rates are between 10 and 40% [8]. Thus, other
biomarkers are required for predicting which patients
will benefit from anti-EGFR antibody therapy.
Amphiregulin (AREG) and Epiregulin (EREG) belong
to the epidermal growth factor (EGF) family, and act as
mitogenic stimulators through binding to EGFRs [9].
Recently, two large studies on AREG and EREG expres-
sion in patients with colorectal cancer who received
Cetuximab were published. Khambata-Ford et al.
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colorectal cancer treated with Cetuximab to identify
genes that were expressed differentially between the dis-
ease control group and the non-responders, demon-
strated that AREG and EREG expression was associated
with progression-free survival [10]. In this study, samples
were collected from the metastatic site. Jacobs et al.
examined 220 colorectal cancer patients treated with
Cetuximab, and reported that there was a significant
association between EREG and AREG expression and the
response to Cetuximab in KRAS wild-type patients, but
not in KRAS mutant patients [11]. Formalin-fixed paraf-
fin-embedded (FFPE) samples from primary colorectal
cancer were used in this study.
These two studies may indicate that AREG and EREG
e x p r e s s i o n ,a sw e l la sK R A Ss t a t u sa c t sa sap r e d o m i -
nant biomarker of sensitivity/resistance to Cetuximab.
However, although the samples were taken from differ-
ent sites in these two studies, there has been no pre-
vious study that has shown the relation between the
gene expressions of AREG and of EREG between the
primary site and a liver metastatic site. There has not as
yet been clear that the gene expression from either pri-
mary or metastatic site is more associated with patients’
prognosis. In addition, although these two independent
studies showed the efficacy of AREG and EREG as pre-
dictive markers for Cetuximab, the clinical importance
of these genes for patients who have not received anti-
EGFR therapy is not clear. These genes are also reported
to be associated with an increased likelihood of liver
metastasis [12,13], which indicates that these genes may
play an important role in the development of metastasis
in malignancies, suggesting that they may be prognostic
markers, even with patients who have never received
anti-EGFR therapy.
Therefore, the aims of our study were: (1) to observe
the relationship of AREG and EREG mRNA expressions
between the primary site of colorectal cancer and the
corresponding liver metastatic site, (2) determine
whether the gene expression from the primary site or
the liver metastatic site is more likely to be associated
with clinical outcome, (3) determine the significance of
AREG and EREG as a prognostic markers for patients
who have not received anti-EGFR therapy, and see their
relation to KRAS mutant status.
Methods
Patients and samples
One hundred and twenty cases of primary colorectal can-
cer with the corresponding liver metastases were analyzed
in this study (70 men and 50 women; median age, 63.5
(range, 32- 91). The metastases in 100 patients were syn-
chronous, and in 20 were metachronous. These patients
had undergone surgical resection of primary colorectal
adenocarcinoma and liver metastasis between 1998 and
2008 at the Department of Gastroenterology, Tokyo
Women’s Medical University, Tokyo, Japan. One hundred
two patients had received fluoropyrimidinebased che-
motherapy after surgery, 6 had never received chemother-
apy and 12 were unknown. No patients had received
neoadjuvant/adjuvant radiotherapy. No patients had ever
received anti-EGFR antibody agents. All of the patients
were Japanese, and all gave their written informed consent
according to the institutional regulations. The characteris-
tics of the 120 patients are shown in Table 1.
Microdissection
Formalin-fixed, paraffin-embedded tumor specimens
were cut into serial sections with a thickness of 10 μm.
For pathological diagnosis, one slide was stained with
H&E and evaluated by a pathologist. Manual microdis-
section using a scalpel was performed if the histology
was homogeneous and contained more than 90% of can-
cer cell tissue. For all other samples, laser-capture
Table 1 Demographic and clinical parameters of patients
with metastatic colorectal cancer
Characteristics Frequency %
Age
Mean (range) 63.5 (32-91)
Gender
Male 70 58.3%
Female 50 41.7%
Anatomical Site
Right colon 35 29.2%
Transverse colon 8 6.7%
Left colon 50 41.7%
Rectum 27 22.5%
Histology
Well differentiated 89 74.2%
Moderately differentiated 27 22.5%
Poor/Mucinous 4 3.3%
Dukes Grade
A 2 1.7%
B 34 28.3%
C 84 70.0%
Liver synchronicity
Synchronous 100 83.3%
Metachronous 20 16.7%
Lymph node metastasis
Positive 84 70.0%
Negative 36 30.0%
Adjuvant chemotherapy
Received 102 85.0%
Not received 6 5.0%
Unknown 12 10%
This study was approved by the ethics committee of Tokyo Women’s Medical
University, and was performed in accordance with the Declaration of Helsinki.
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Munich, Germany) was performed to ensure that only
tumor cells were dissected.
RNA isolation and cDNA synthesis
RNA isolation from formalin-fixed paraffin-embedded
(FFPE) specimens was performed using an RNeasy FFPE
Kit (Qiagen, Tokyo, Japan) according to the manufac-
turer’s instructions. From the total RNA yielded, cDNA
was converted using a High Capacity cDNA Reverse
Transcription Kit (Applied Biosystems, Tokyo, Japan).
Reverse transcription-PCR
cDNA was pre-amplified using a Taqman PreAmp Mas-
ter Mix Kit (Applied Biosystems, Tokyo, Japan) accord-
ing to the manufacturer’s instructions. Quantification of
AREG and EREG and internal reference gene (beta-2-
microglobulin) was done using a fluorescence-based
real-time detection method (StepOne real-time PCR sys-
tem, Applied Biosystems Inc., Tokyo, Japan). Single
internal reference gene (Beta-2-microglobulin) was used
in this study. The primers and probes used were from
Taqman Gene Expression Assays (Applied Biosystem
Inc.), Assay IDs were Hs00950669_m1 for AREG,
Hs00914312_m1 for EREG, and Hs99999907_m1 for
beta-2-micoroglobulin. The PCR reaction mixture con-
sisted of 10 μl of Taqman Fast Universal PCR Master
Mix, No UNG (Applied Biosystem Inc.), 5 μl of pream-
plified cDNA sample, 1 μlo fT a q m a nG e n eE x p r e s s i o n
Assays primers and probe (20×), and 3 μl of Nuclease-
Free Water. Cycling conditions were 95°C for 20 sec-
onds, followed by 40 cycles at 95°C for 1 second and 60°
C for 20 seconds. The threshold cycle (CT) value for
each gene was determined by SDS software v1.2
(Applied Biosystems). Delta-CT(ΔCT) value, which is
the difference between the CT value of the target gene
and the CT value of the endogenous control gene was
also calculated by the same software. Delta-ΔCT
(ΔΔCT), which is the difference in the ΔCT value for
each sample and the highest ΔCT value as a calibrator,
was calculated. The 2
-ΔΔCT number was used for relative
mRNA quantification.
Median values were used as the cut-off values to
divide high and low expression.
KRAS mutation screening
DNA was extracted from FFPE specimens using the
Qiamp DNA FFPE tissue Kit (Qiagen, Tokyo, Japan)
according to the manufacturer’s instructions. Concentra-
tions were measured with the ND-1000 Spectrophot-
ometer (NanoDrop Technologies, Wilmington, DE,
USA), and 500 μg of DNA was added to a 6 μlo ff o r -
ward and reverse primer and 25 μlo fQ u i c kT a gH S
DyeMix (Toyobo, Osaka, Japan). Primers that spanned
codons 12 and 13 of the KRAS gene were: forward, 5’–
GAATGGTCCTGCACCAGTAA-3’;a n dr e v e r s e ,5 ’-
GTGTGACATGTTCTAATATAGTCA-3’. PCR cycling
was run according to the followingconditions: one cycle
of 94°C for 3 minutes, 40 cycles of 94°C for 30 seconds,
56°C for 30 seconds, and 72°C for 45 seconds; and one
cycle of 72°C for 10 minutes.
PCR products were purified using the MinElute PCR
Purification Kit (Qiagen). The purified PCR product was
then used as a template in cycle sequencing with the
Dye Terminator Cycle Sequencing (DTCS) Quick Start
Kit (Beckman Coulter, Tokyo, Japan) according to the
manufacturer’s instructions. Nested PCR primer
sequences were Forward: 5’-GTCCTGCACCAGTAA-
TATGC; reverse: 5’-ATGTTCTAATATAGTCA-
CATTTTC-3’. Sequencing reactions were precipitated
with ethanol, and run on a CEQ-8800 Genetic Analyzer
(Beckman Coulter). Direct sequencing was performed in
duplicate for each sample.
Statistical analysis
The comparisons between the median mRNA levels of
the primary tumor and the corresponding liver metas-
tases, median mRNA levels of KRAS mutant and wild-
type were assessed using the Wilcoxon signed-rank test.
The correlation between the mRNA levels of primary
tumor and of liver metastases was assessed using Spear-
man’s rank correlation. The Kaplan-Meier method was
used for survival curves, and the log-rank test was used
for statistical analysis. Overall survival was defined as
the time from the day of primary tumor resection to
death from any cause. Multivariate analyses were per-
formed by Cox proportional hazard model. Statistical
significance was recognized at P-values of less than 0.05.
All values were two-sided.
Results
AREG and EREG relative mRNA expression levels in
primary colorectal cancer and liver metastases
There were no significant differences of median AREG
and EREG relative mRNA levels between primary tumor
and liver metastases (AREG: primary vs. liver = 0.16 vs.
0.21, p = 0.34, EREG: 0.030 vs. 0.034, p = 0.057) (Table 2).
Table 2 Median Values of AREG and EREG mRNA in
primary tumor and liver metastases
Primary tumor Liver metastases P-value
AREG (median) 0.16 0.21 0.34
(range) (0.00-3.74) (0.00-3.67) N.S.
EREG (median) 0.030 0.034 0.057
(range) (0.00-0.256) (0.00-0.419) N.S.
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primary tumor and liver metastases
Modest, but significant correlation was seen with respect
to AREG mRNA expression between primary tumor and
corresponding liver metastases (Rs = 0.57, p < 0.0001)
(Figure 1a). The same results were observed in EREG
mRNA expression (Rs = 0.53, p < 0.0001) (Figure 1b).
Regarding AREG expression, the correlation coefficient
(Rs) was 0.357 in the patients with synchronous metas-
tases, and 0.60 in those with metachronous metastases.
Regarding EREG expression, the correlation coefficient
(Rs) was 0.58 in the patients with synchronous metas-
tases, and 0.36 in those with metachronous metastases.
Correlation of expression levels between AREG and EREG
Strong correlations were observed between AREG mRNA
expression and EREG mRNA expression in both the pri-
mary site (Rs = 0.82, p < 0.0001) (Figure 2a), and in the
liver metastatic sites (Rs = 0.87, p < 0.0001) (Figure 2b).
AREG and EREG expression and KRAS status
KRAS status was evaluated in 110 patients. Sixty-five
(59%) patients showed the KRAS wild-type, and 45
(41%) showed the mutant type. No differences of med-
ian AREG or EREG mRNA levels were observed
between KRAS wild-type and mutant types in the pri-
mary site (AREG: wild-type vs. mutant = 0.15 vs. 0.17; p
= 0.40, EREG: wild-type vs. mutant = 0.027 vs 0.030; p
= 0.45) or the liver metastatic site (AREG: 0.18 vs. 0.17;
p = 0.86, EREG: 0.043 vs. 0.035; p = 0.73).
AREG and EREG expression and overall survival by KRAS
status
There was no difference in overall survival between the
patients with KRAS wild-type and those with mutant
type (p = 0.71). When all 120 patients were analyzed,
there were no survival differences between the patients
with high AREG expression and those with low expres-
sion (p = 0.92), or between the patients with high EREG
expression and those with low expression (p = 0.84) in
the primary site. However, after division by KRAS status,
the patients with low EREG expression in the primary
tumor had significantly better overall survival than those
with high expression in the KRAS wild-type group (p =
0.018, median survival time: 2222 days vs. 1190 days)
(Figure 3a). The opposite result was observed in the
KRAS mutant group; the patients with high EREG
expression in primary tumor had better survival than
those with low expression (p = 0.045, median survival
time: high vs. low = 1743 days vs 1113 days) (Figure
3b). With respect to AREG expression in primary site,
no statistical differences were observed in overall survi-
val between the patients with low AREG expression and
those with high expression either among the KRAS
wild-type group (p = 0.16) or among the KRAS mutant
group (p = 0.18). The relative mRNA expression levels
in the liver metastatic sites did not correlate with overall
survival time either among the KRAS wild-type group
(AREG, p = 0.26; EREG: p = 0.28), or among the KRAS
mutant group (AREG: p = 0.81, EREG: p = 0.63).
In multivariate analysis, low EREG expression in the
primary tumor site was significantly related to better
overall survival (p = 0.006) in KRAS wild-type patient
group, as well as lymph node metastasis (p = 0.014)
(Table 3)
Discussion
In this study, modest correlations of AREG and EREG
relative mRNA expression were observed between primary
colorectal cancer and corresponding liver metastases. We
Figure 1 Correlation of mRNA expression between primary colorectal cancer and corresponding liver metastases.F i g u r e1 - a :A R E G
mRNA expression; correlation coefficient (Rs) = 0.57, p < 0.0001. Figure 1-b: EREG mRNA expression; Rs = 0.53, p < 0.0001.
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EGFR [15], and 5-FU metabolism-related genes [16]
between primary colorectal tumor and liver metastases.
Although EGFR mRNA expression showed a relatively
strong correlation between the primary tumor and metas-
tases [15], the correlations of AREG and EREG, which are
the ligands of the EGFR family, between primary and
metastases were weaker than that. The median values of
AREG and EREG expression did not differ between pri-
mary cancer and metastases, which suggested that there
was no up-regulation in the liver metastases. The strength
of correlation was similar between synchronous and meta-
chronous metastases, which suggested that expression
levels were well preserved, even in relapse, for long time
after primary tumor resection. Interestingly, the signifi-
cance of EREG as a prognostic biomarker, which was
observed in this study, was seen only on expression from
the primary tumor, not on expression from the liver
metastases. This data suggests that the expression from
primary tumor reflects biological malignancy, and this
relationship weakens in metastatic lesions after various
biological modifications in the process of metastasis.
In this study, low EREG expression levels from pri-
mary tumors were significantly associated with overall
survival only among patients with KRAS wild-type sta-
tus. Although several previous reports demonstrated the
association between EREG (and/or AREG) expression
and survival time in KRAS wild-type patients who had
received Cetuximab [10,11,17-19], no previous paper
reported the association in colorectal cancer patients
who had never received anti-EGFR antibody. The reason
that this association was observed only in KRAS wild-
Figure 2 Correlation of mRNA expression between AREG and EREG in primary colorectal cancer (2-a) and liver metastases (2-b). Figure
2-a: primary site; correlation coefficient (Rs) = 0.82, p < 0.0001. Figure 2-b: metastatic site; Rs = 0.87, p < 0.0001.
Figure 3 Kaplan-Meier Curve of overall survival by EREG mRNA expression in KRAS wild-type group (3-a) and KRAS mutant group (3-
b). Figure 3-a: KRAS wild-type group (p = 0.018, median survival; low vs high = 2222 vs 1190 days). Figure 3-b: KRAS mutant group (p = 0.045;
median survival; low vs high = 1113 vs 1743 days). Cut-off line: median value of EREG expression levels.
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signal pathway depends mainly on the binding of ligands
such as AREG and EREG to HER receptors in KRAS
wild-type individuals, which suggests that higher expres-
sion of ligands results in up-regulation of this pathway
and leads to cancer cell proliferation and the likelihood
of metastasis. On the other hand, it is believed that
KRAS mutations can lead to dysregulation of this path-
way and downstream signaling in the absence of ligand-
dependent receptor activation [10], and this suggested
that the expression of ligands cannot be the main regu-
lating factor of this pathway in KRAS mutant indivi-
duals. In our data, the patients with high EREG
expression showed longer survival time in KRAS mutant
patients (p = 0.045), in contrast to that in KRAS wild-
type patients. However, since the numbers of patients
with KRAS mutant were relatively small and the p-value
was close to the significance level, this finding may not
be reproducible, and probably needs to be validated.
Recently, several studies have reported that AREG
(and EREG) expression was associated with the likeli-
hood of liver metastasis in colorectal cancer, and sug-
gested that it might play an important role in the
development of liver metastasis [12,13]. In our study, a
significant relationship was observed between EREG
expression and patient survival, although all of the
patients involved had liver metastases. This fact
indicates that EREG and AREG expression is not only
associated with the likelihood of metastasis but is also
involved in tumor progression and biological malig-
nancy. The association between these types of gene
expression and survival time was also reported in other
tumor types, such as non-small cell lung cancer [20]
and oral squamous cell carcinoma [21]. These data sug-
gested that EREG and AREG expression is not only a
predictive biomarker for patients who have received
anti-EGFR therapy, but is also a prognostic biomarker
for a various types of cancer patients.
Conclusions
In summary, this is the first study which showed the
correlation of AREG and EREG mRNA expression
between primary and corresponding liver metastases.
This study also showed the significance of EREG
mRNA expression as prognostic marker in patients
with KRAS wild-type. These data appear to support the
fact that this HER family signaling pathway plays a
very important role in tumor progression, and blocking
this pathway is a reasonable strategy for the treatment
of colorectal cancer.
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